title

March 7, 2007

Article

description

body

Related Videos

Related Content

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Lifestyle Interventions for ADHD

Do Clothes Make the Psychiatrist?

September 27th 2023

Here's to a Psychedelic Revolution

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Bleeding Risk With SSRIs, Part 1: Cardiovascular and Cerebrovascular Considerations

September 26th 2023

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Lifestyle Interventions for ADHD

Do Clothes Make the Psychiatrist?

September 27th 2023

Here's to a Psychedelic Revolution

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Bleeding Risk With SSRIs, Part 1: Cardiovascular and Cerebrovascular Considerations

September 26th 2023

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Lifestyle Interventions for ADHD

Do Clothes Make the Psychiatrist?

September 27th 2023

Here's to a Psychedelic Revolution

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

Bleeding Risk With SSRIs, Part 1: Cardiovascular and Cerebrovascular Considerations

September 26th 2023

Related Content

The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”

NDA Submitted for Investigational Muscarinic Antipsychotic in the Treatment of Schizophrenia

September 28th 2023

Lifestyle Interventions for ADHD

Lifestyle Interventions for ADHD

white coat

Do Clothes Make the Psychiatrist?

September 27th 2023

Here's to a Psychedelic Revolution

Here's to a Psychedelic Revolution

The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.

Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD

September 26th 2023

bleeding

Bleeding Risk With SSRIs, Part 1: Cardiovascular and Cerebrovascular Considerations

September 26th 2023

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.